Key result
Nebivolol, a third-generation beta-blocker with vasodilatory properties, is clinically effective as an initial or add-on therapy for systemic hypertension, angina, and heart failure.
Nebivolol is a third-generation beta-blocker with unique vasodilatory properties that make it an effective and potentially better-tolerated treatment option for hypertension, angina, and heart failure.
No takes yet. Share an insight, caveat, or question.
May support nebivolol selection based on ancillary effects; leaves open need for randomized head-to-head trials.
Jonathan G. Howlett (2014) conducted a review in Cardiovascular disease. Nebivolol was evaluated. Nebivolol, a third-generation beta-blocker with vasodilatory properties, is clinically effective as an initial or add-on therapy for systemic hypertension, angina, and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: